$823.82▴ 3.10%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Regeneron Pharmaceuticals, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days9 articles
5 bullish4 neutral0 bearish
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Press Release : Availability of the aide-mémoire for Q3 2026 results
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?Homozygous Familial Hypercholesterolemia (HoFH) - 7MM Market, Epidemiology, and Forecast - 2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities